SKYE
Skye Bioscience, Inc.
1.80$
+0.8%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | -100.0% | – | – | – | – | – | – | – | – | – | – | |
| – | -1.5% | -2.9% | +8.1% | +121.5% | +165.6% | +1.2% | +5.5% | – | – | -4.0% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +26.8% | +22.3% | +109.5% | +19.7% | +59.6% | -7.6% | +99.2% | -34.7% | +22.6% | -32.3% | -49.2% | – | |
| – | +11.6% | +68.6% | +2.9% | +7.2% | -1.8% | +0.2% | -14.4% | +0.0% | -12.3% | +38.3% | -18.3% | – | |
| – | -83.5% | +50.6% | +36.6% | -40.9% | +114.7% | +10.3% | +55.1% | -27.3% | +12.3% | -16.1% | -11.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +58.5% | +1.6% | +3.0% | -35.3% | +47.3% | -99.7% | -100.0% | – | – | – | +50.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -436.5% | – | +303.6% | – | – | – | +70.0% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.